Search
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411] … [A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections.
Biotin
go.drugbank.com/drugs/DB00121ApprovedInvestigationalNutraceuticalA water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
Mixtures: Multi II IV Vi Tab, Vc IIProducts: BIO-H-TIN Vitamin H 5 mg - Tabletten, BIO-H-TIN Vitamin H 2,5 mg - TablettenDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Daridorexant reduces overactive wakefulness: in the investigational trials, daridorexant reportedly improved sleep and daytime functioning in patients with insomnia.
Padimate A
go.drugbank.com/drugs/DB11229ApprovedWithdrawnIn Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens. … Padimate A is an ester derivative of PABA and an ingredient in some sunscreens.
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalPatients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. … In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free
Categories: Compounds used in a research, industrial, or household settingSilicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or … Stage II Mycosis Fungoides).
Mixtures: Procosa II, Calcium With Mg Zn Mn Cu CR Si and Vit. C & DTisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalIt was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Glipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigationalAccording to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S.
Synonyms: N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaCategories: Drugs Used in DiabetesCoagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalHowever its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET